European Unified Registries for Heart Care Evaluation and Randomised Trials Italy (EuroHeart ITA)

January 7, 2026 updated by: Heart Care Foundation

European Unified Registries for Heart Care Evaluation and Randomised Trials

Major advances in cardiovascular medicine have been driven by innovations in basic research in biological and technical sciences. Despite the clear evidence regarding the treatments that have been demonstrated to be useful to improve patients' outcomes, their transferability to everyday clinical practice seems to be at least suboptimal. The European Society of Cardiology (ESC), therefore, planned to support a program, denominated EuroHeart, for continuous data collection of standardized and/or harmonized variables in common cardiovascular diseases, such as ACS, HF and A Fib. EuroHeart is an observational, prospective, multicentre initiative with continuous data collection in consecutive patients with ACS, HF and A Fib to support continuous quality of care improvement through the evaluation of quality indicators (QIs) defined by the ESC. All patients included in the EuroHeart initiative, will enter a 12 month longitudinal follow-up with the collection of clinical events and clinical status data.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
5000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • Italy
      • Novara, Italy, 28100
        • Recruiting
        • Aou Maggiore Della Carita' - Ssvd Utic
        • Contact:
    • AREZZO
    • BA
      • Acquaviva delle Fonti, BA, Italy, 70021
      • Altamura, BA, Italy, 70022
      • Bari, BA, Italy, 70123
        • Recruiting
        • Ospedale San Paolo - Cardiologia-Utic
        • Contact:
      • Bari, BA, Italy, 70131
        • Recruiting
        • Ospedale Di Venere - U.O.C. Di Cardiologia
        • Contact:
    • BS
      • Brescia, BS, Italy, 25123
        • Recruiting
        • Asst Spedali Civili - Cardiologia
        • Contact:
    • CAGLIARI
      • Monserrato, CAGLIARI, Italy, 09124
        • Active, not recruiting
        • A.O.U. Cagliari Policlinico Monserrato - Sc Cardiologia Utic Emodinamica
    • CATANIA
      • Catania, CATANIA, Italy, 95126
        • Recruiting
        • Azienda Ospedaliera Cannizzaro - Uoc Cardiologia
        • Contact:
    • CB
    • CE
      • Caserta, CE, Italy, 81100
        • Recruiting
        • Azienda Ospedaliera S. Anna E S. Sebastiano - U.O. Cardiologia D'Emergenza Con Utic
        • Contact:
      • Maddaloni, CE, Italy, 81024
        • Recruiting
        • Casa Di Cura San Michele - Uo Cardiologia
        • Contact:
    • CR
      • Cremona, CR, Italy, 26100
        • Active, not recruiting
        • Ospedale Di Cremona - Uo Di Cardiologia
    • CS
    • CZ
      • Catanzaro, CZ, Italy, 88100
        • Not yet recruiting
        • P.O. "Pugliese" - A.O.U. "Renato Dulbecco" - Utic-Emodinamica E Cardiologia Interventistica
        • Contact:
    • FG
    • FI
      • Empoli, FI, Italy, 50053
      • Florence, FI, Italy, 50134
        • Active, not recruiting
        • Aou Careggi - Interventistica Cardiologica Strutturale
    • GE
      • Genova, GE, Italy, 16132
        • Recruiting
        • Irccs Ospedale Policlinico San Martino - Unita' Operativa Cardiologia
        • Contact:
    • MESSINA
      • Messina, MESSINA, Italy, 98124
        • Recruiting
        • Irccs Centro Neurolesi Bonino Pulejo - P.O. Piemonte - Cardiologia E Utic
        • Contact:
      • Messina, MESSINA, Italy, 98124
    • MILANO
    • Mlano
      • Milan, Mlano, Italy, 20162
        • Active, not recruiting
        • Asst Ospedale Metropolitano Niguarda - Cardiologia 1 - Emodinamica
    • NAPOLI
      • Napoli, NAPOLI, Italy, 80131
        • Recruiting
        • Aou Federico Ii - Uoc Cardiologia Emodinamica Ed Utic
        • Contact:
    • PALERMO
      • Palermo, PALERMO, Italy, 90127
        • Active, not recruiting
        • Aou Policlinico P. Giaccone - U.O.C. Cardiologia
      • Palermo, PALERMO, Italy, 90146
    • PD
      • Padua, PD, Italy, 35128
        • Active, not recruiting
        • Azienda Ospedale-Universita Padova - Uosd Terapia Intensiva Cardiologica
    • PE
    • PG
      • Perugia, PG, Italy, 06129
        • Not yet recruiting
        • Azienda Ospedaliera Di Perugia - S.C. Cardiologia
        • Contact:
    • PR
      • Fidenza, PR, Italy, 43036
        • Recruiting
        • Ospedale Civile - U.O.C. Cardiologia - Utic
        • Contact:
    • PU
    • RE
    • RG
      • Ragusa, RG, Italy, 97100
        • Recruiting
        • Ospedale Giovanni Paolo Ii - U.O.C. Cardiologia-Utic
        • Contact:
    • RIETI
      • Rieti, RIETI, Italy, 02100
        • Recruiting
        • P.O. San Camillo de Lellis - U.O.C. Cardiologia
        • Contact:
    • RM
      • Roma, RM, Italy, 00128
        • Not yet recruiting
        • Campus Biomedico - Cardiologia
        • Contact:
      • Roma, RM, Italy, 00135
      • Roma, RM, Italy, 00157
        • Not yet recruiting
        • Ospedale Sandro Pertini - Uoc Cardiologia - Utic
        • Contact:
      • Roma, RM, Italy, 00169
      • Roma, RM, Italy, 00177
        • Recruiting
        • Ospedale Madre Giuseppina Vannini - U.O.C. Cardiologia
        • Contact:
    • RO
      • Rovigo, RO, Italy, 45100
        • Recruiting
        • Ospedale Santa Maria Della Misericordia - U.O.C. Cardiologia
        • Contact:
    • SA
      • Vallo della Lucania, SA, Italy, 84078
        • Recruiting
        • Ospedale San Luca - U.O. Utic - Cardiologia
        • Contact:
    • SI
    • SV
      • Savona, SV, Italy, 17100
        • Recruiting
        • P.O. Levante - Ospedale San Paolo - S.C. Cardiologia Levante
        • Contact:
    • TO
    • TRENTO
      • Rovereto, TRENTO, Italy, 38068
        • Recruiting
        • Ospedale Santa Maria Del Carmine - U.O. Cardiologia Ad Indirizzo Elettrofisiologia
        • Contact:
      • Trento, TRENTO, Italy, 38122
        • Recruiting
        • OSPEDALE SANTA CHIARA - Divisione di Cardiologia
        • Contact:
    • TS
      • Trieste, TS, Italy, 34149
    • TV
    • UD
      • Udine, UD, Italy, 33100
        • Recruiting
        • Pou "Santa Maria Della Misericordia" - S.O.C. Cardiologia
        • Contact:
    • VARESE
    • VI
      • Arzignano, VI, Italy, 36071
    • VR
      • Negrar, VR, Italy, 37024
      • Verona, VR, Italy, 37126
        • Active, not recruiting
        • Aoui Di Verona - U.O. Cardiologia

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

patients with ACS

Description

Inclusion Criteria:

  • Patients ≥18 years of age.
  • Males and females at birth.
  • At least one of the following clinical conditions:
  • Hospitalization for Acute Coronary Syndrome (ACS)
  • Heart failure (HF, outpatients, and/or inpatients)
  • Atrial fibrillation (A Fib, outpatients and/or inpatients)
  • Signed informed consent for the study and for privacy.

Exclusion Criteria:

  • patients who do not sign the consent to participate in the project and/or Privacy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Adherence to ESC Quality indicators (STEMI patients reperfused)
Time Frame: From enrollment to 12 months follow-up
Proportion of patients with STEMI reperfused among those eligible (onset of symptoms to diagnosis <12 hours)
From enrollment to 12 months follow-up
Adherence to ESC Quality indicators (STEMI patients reperfused <90 min)
Time Frame: From enrollment to 12 months follow-up
Proportion of patients with STEMI who receive timely reperfusion with PCI (wire crossing) within 90 minutes from initial diagnostic ECG
From enrollment to 12 months follow-up
Adherence to ESC Quality indicators (coronary angiography in NSTEMI patients within 24 hours)
Time Frame: From enrollment to 12 months follow-up
Rate of NSTEMI patients who receive invasive within 24 hours from their diagnosis
From enrollment to 12 months follow-up
Adherence to ESC Quality indicators (radial access)
Time Frame: From enrollment to 12 months follow-up
Use of radial access in case of invasive strategy for patients with STEMI and NSTEMI
From enrollment to 12 months follow-up
Adherence to ESC Quality indicators (time to reperfusion in STEMI patients)
Time Frame: From enrollment to 12 months follow-up
The time between the initial STEMI diagnosis and arterial access (absolute value) for primary PCI
From enrollment to 12 months follow-up
Adherence to ESC Quality indicators (pre-discharge LVEF evaluation in STEMI and NSTEMI patients)
Time Frame: From enrollment to 12 months follow-up
The proportion of patients with STEMI and NSTEMI who have an assessment of their left ventricular ejection fraction (LVEF) before hospital discharge
From enrollment to 12 months follow-up
Adherence to ESC Quality indicators (in hospital LDL-c evaluation in STEMI and NSTEMI patients)
Time Frame: From enrollment to 12 months follow-up
The proportion of patients with STEMI and NSTEMI who have their LDL cholesterol measured during hospitalization
From enrollment to 12 months follow-up
Adherence to ESC Quality indicators (DAPT prescription at discharge in STEMI and NSTEMI patients)
Time Frame: From enrollment to 12 months follow-up
Proportion of patients with STEMI and NSTEMI discharged on dual antiplatelet therapy
From enrollment to 12 months follow-up
Adherence to ESC Quality indicators (LLA prescription at discharge in STEMI and NSTEMI patients)
Time Frame: From enrollment to 12 months follow-up
Proportion of patients discharged from hospital on Lipid Lowering Agents (LLA)
From enrollment to 12 months follow-up
Adherence to ESC Quality indicators (ACEi/ARB/ARNI prescription at discharge in patients with LVEF ≤40%)
Time Frame: From enrollment to 12 months follow-up
Proportion of patients with LVEF ≤40% who are discharged from hospital on angiotensin converting enzymes inhibitors (ACEi) or angiotensin receptor blockers (ARBs) or angiotensin receptor-neprilysin inhibitor (ARNI)
From enrollment to 12 months follow-up
Adherence to ESC Quality indicators (Beta blockers prescription at discharge in patients with LVEF ≤40%)
Time Frame: From enrollment to 12 months follow-up
Proportion of patients with LVEF ≤40% who are discharged from hospital on beta blockers.
From enrollment to 12 months follow-up

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Cardiovascular and non-cardiovascular events during follow-up
Time Frame: 12 months follow-up
Proportion of patients with clinical events at 12 months
12 months follow-up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Heart Care Foundation

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
September 15, 2024

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
September 15, 2027

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 30, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
December 2, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 2, 2025

First Posted (Estimated)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
December 16, 2025

Study Record Updates

Last Update Posted (Estimated)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
January 12, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 7, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
January 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • K27

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings